The DOI matches its Crossref record.
Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206–1
Abstract
Purpose: To evaluate the survival benefit of adjuvant chemotherapy after curative resection in serosa-negative gastric cancer patients (excluding patients who were T1N0), we conducted a multicenter phase III clinical trial in which 13 cancer centers in Japan participated. Patients and Methods: From January 1993 to December 1994, 252 patients were enrolled into the study and allocated randomly to adjuvant chemotherapy or surgery alone. The chemotherapy comprised intravenous mitomycin 1.33 mg/m 2, fluorouracil (FU) 166.7 mg/m 2, and cytarabine 13.3 mg/m 2 twice weekly for the first 3 weeks after surgery, and oral FU 134 mg/m 2 daily for the next 18 months for a total dose of 67 g/m 2. The primary end point was relapse-free survival. Overall survival and the site of recurrence were secondary end points. Results: Ninety-eight percent of patients underwent gastrectomy with D2 or greater lymph node dissection. There were no treatment-related deaths and few serious adverse events. There was no significant difference in relapse-free and overall survival between the arms (5-year relapse-free survival 88.8% chemotherapy v 83.7% surgery alone; P = .14 and 5-year survival 91.2% chemotherapy v 86.1% surgery alone; P = .13, respectively). Nine patients (7.1%) in the chemotherapy arm and 17 patients (13.8%) in the surgery-alone arm had cancer recurrence. Conclusion: There was no statistically significant relapse-free or overall survival benefit with this adjuvant chemotherapy for patients with macroscopically serosa-negative gastric cancer after curative resection, and there was no statistical difference between the two arms relating to the types of cancer recurrence. We do not recommend adjuvant chemotherapy with this regimen for this population in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072252 · Cited by 2,517
Self-citationHartgrink, H. H., van de Velde, C. J. H., Putter, H., Bonenkamp, J. J., Klein Kranenbarg, E., Songun, I., Welvaart, K., van Krieken, J. H. J. M., Meijer, S., Plukker, J. T. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.026 · Cited by 918
Self-citationOba, K., Paoletti, X., Alberts, S., Bang, Y.-J., Benedetti, J., Bleiberg, H., Catalano, P., Lordick, F., Michiels, S., Morita, S., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt270 · Cited by 168
Self-citation
Metadata
- Authors
- Nashimoto, A., Nakajima, T., Furukawa, H., Kitamura, M., Kinoshita, T., Yamamura, Y., Sasako, M., Kunii, Y., Motohashi, H., Yamamoto, S., & the Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group
- Venue
- Journal of Clinical Oncology
- Published
- 2003-06-15
- Volume
- 21
- Issue
- 12
- Pages
- 2282-2287
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2065887320
- Cited by
- 164
- References
- 0
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206–1. https://app.cochat.ai/papers/10.1200/jco.2003.06.103
- The paper
- Nashimoto, A., Nakajima, T., Furukawa, H., Kitamura, M., Kinoshita, T., Yamamura, Y., Sasako, M., Kunii, Y., Motohashi, H., Yamamoto, S., & the Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group. (2003). Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206–1. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.06.103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.